Target Price | $194.25 |
Price | $131.32 |
Potential | 47.92% |
Number of Estimates | 28 |
28 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $194.25. This is 47.92% higher than the current stock price. The highest price target is $342.00 160.43% , the lowest is $135.00 2.80% . | |
A rating was issued by 36 analysts: 17 Analysts recommend Biogen to buy, 19 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 47.92% . Most analysts recommend the Biogen stock at Hold. |
31 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.2b . This is 0.75% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $9.9b 6.84% , the lowest is $9.0b 3.20% .
This results in the following potential growth metrics:
2024 | $9.3b | 1.60% |
---|---|---|
2025 | $9.2b | 0.75% |
2026 | $9.1b | 1.05% |
2027 | $9.2b | 1.51% |
2028 | $9.4b | 1.72% |
2029 | $9.4b | 0.26% |
11 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.4b . This is 20.60% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.8b 37.52% , the lowest is $2.8b 1.28% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $2.8b | 31.57% |
---|---|---|
2025 | $3.4b | 20.60% |
2026 | $3.3b | 2.78% |
2027 | $3.4b | 4.23% |
2028 | $3.9b | 15.21% |
2029 | $4.3b | 10.28% |
2024 | 30.19% | 33.71% |
---|---|---|
2025 | 36.68% | 21.51% |
2026 | 36.04% | 1.74% |
2027 | 37.00% | 2.66% |
2028 | 41.91% | 13.27% |
2029 | 46.33% | 10.55% |
11 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $1.9b . This is 13.99% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.3b 40.25% , the lowest is $1.5b 10.91% .
This results in the following potential growth metrics and future Net Margins:
2024 | $1.6b | 40.40% |
---|---|---|
2025 | $1.9b | 13.89% |
2026 | $2.2b | 16.10% |
2027 | $2.3b | 6.84% |
2028 | $2.6b | 12.86% |
2029 | $2.7b | 2.00% |
2024 | 17.61% | 42.68% |
---|---|---|
2025 | 20.20% | 14.73% |
2026 | 23.70% | 17.33% |
2027 | 24.95% | 5.27% |
2028 | 27.68% | 10.94% |
2029 | 28.31% | 2.28% |
11 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $12.74 . This is 13.95% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.68 40.25% , the lowest is $9.96 10.91% .
This results in the following potential growth metrics and future valuations:
2024 | $11.19 | 40.40% |
---|---|---|
2025 | $12.74 | 13.85% |
2026 | $14.80 | 16.17% |
2027 | $15.81 | 6.82% |
2028 | $17.84 | 12.84% |
2029 | $18.20 | 2.02% |
Current | 11.74 | 56.55% |
---|---|---|
2025 | 10.30 | 12.27% |
2026 | 8.88 | 13.79% |
2027 | 8.31 | 6.42% |
2028 | 7.36 | 11.43% |
2029 | 7.22 | 1.90% |
Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.56 and an P/S ratio of 2.09 .
This results in the following potential growth metrics and future valuations:
Current | 2.54 | 36.66% |
---|---|---|
2025 | 2.56 | 0.87% |
2026 | 2.59 | 1.07% |
2027 | 2.55 | 1.49% |
2028 | 2.51 | 1.70% |
2029 | 2.51 | 0.26% |
Current | 2.07 | 37.68% |
---|---|---|
2025 | 2.09 | 0.76% |
2026 | 2.11 | 1.06% |
2027 | 2.08 | 1.49% |
2028 | 2.05 | 1.70% |
2029 | 2.05 | 0.26% |
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Feb 18 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 13 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Feb 13 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Feb 13 2025 |
BMO Capital |
Market Perform
➜
Market Perform
|
Unchanged | Feb 13 2025 |
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Feb 13 2025 |
Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Feb 13 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Feb 18 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Feb 13 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Feb 13 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Feb 13 2025 |
Unchanged
BMO Capital:
Market Perform
➜
Market Perform
|
Feb 13 2025 |
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Feb 13 2025 |
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Feb 13 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.